Although classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events, impacts on quality of life and poor outcomes in older patients present ongoing unmet needs. Much research is currently focused on risk stratification, such as with positive emission tomography (PET) scans, to identify patients who are at low- or high-risk of recurrence and enable the use of risk-adapted approaches. Furthermore, longer-term follow-up data from trials of novel immunotherapy combinations in the frontline setting have recently been presented which demonstrate durable remissions and may reduce the risk of relapse for patients with classical Hodgkin lymphoma.

In this podcast, Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands; Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA; Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, and Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, share updates on the use of PET in the treatment and management of Hodgkin lymphoma, as well as five-year follow-up data from the ECHELON-1 and CheckMate 205 trials, as presented at the 2021 International Conference on Malignant Lymphoma (ICML) and this year’s European Hematology Association (EHA) Congress.

The post EHA & ICML 2021: updates in Hodgkin lymphoma appeared first on VJHemOnc.